Multicenter Observational Study of Myotonic Dystrophy Type 1 (MOS-DM1/POP)
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1
Sponsor: Biogen
A observational or N/A phase clinical study on Myotonic Dystrophy Type 1, this trial is completed. The trial is conducted by Biogen and has accumulated 12 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 7 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Aug 2017 — Nov 2017 [monthly]
Active Not Recruiting NA
-
Mar 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Mar 2017 [monthly]
Recruiting NA
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biogen
- Muscular Dystrophy Association
- Myotonic Dystrophy Foundation
- National Institute of Neurological Disorders and Stroke (NINDS)
- Ohio State University
- Stanford University
- The Marigold Foundation
- University of Florida
- University of Kansas Medical Center
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .